Primary Biliary Cholangitis

Gastroenterology·MeSH: Liver Cirrhosis, Biliary

Prevalence

30.0 / 100K

10 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
ocaliva	INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Phase 3(6)

Drug	Company
2mg cs0159	X4 Pharmaceuticals, Inc (XFOR)
bezafibrate	INTERCEPT PHARMACEUTICALS, INC. (ICPT)
fdc	INTERCEPT PHARMACEUTICALS, INC. (ICPT)
oca	INTERCEPT PHARMACEUTICALS, INC. (ICPT)
oca + bezafibrate	INTERCEPT PHARMACEUTICALS, INC. (ICPT)
volixibat	Mirum Pharmaceuticals, Inc. (MIRM)

Phase 2(2)

Drug	Company
CNP-104	IRONWOOD PHARMACEUTICALS INC (IRWD)
Setanaxib	Calliditas Therapeutics AB (CALT)

Phase 1/Phase 2(1)

Drug	Company
golexanolone	COGNITION THERAPEUTICS INC (CGTX)

BioSniper tracks 10 drugs in development for Primary Biliary Cholangitis across 6 companies.

There are 6 clinical trials targeting Primary Biliary Cholangitis tracked by BioSniper.

The estimated prevalence of Primary Biliary Cholangitis is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.